Isocoumarins: a new class of selective carbonic anhydrase IX and XII inhibitors.


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2022
Historique:
entrez: 21 2 2022
pubmed: 22 2 2022
medline: 22 3 2022
Statut: ppublish

Résumé

Isocoumarins, isomeric to comarins which act as effective carbonic anhydrase (CA, EC 4.2.1.1) inhibitors, were investigated for the first time as inhibitors of this enzyme. A series of 3-substituted and 3,4-disubstituted isocoumarins incorporating phenylhydrazone, 1-phenyl-pyrazole and pyrazolo-substituted pyrimidine trione/thioxo-pyrimidine dione moieties were investigated for their interaction with four human (h) CA isoforms, hCA I, II, IX and XII, known to be important drug targets. hCA I and II were not inhibited by these compounds, whereas hCA IX and XII were inhibited in the low micromolar range by the less bulky derivatives. The inhibition constants ranged between 2.7-78.9 µM against hCA IX and of 1.2-66.5 µM against hCA XII. As for the coumarins, we hypothesise that the isocoumarins are hydrolysed by the esterase activity of the enzyme with formation of 2-carboxy-phenylacetic aldehydes which act as CA inhibitors. Isocoumarins represent a new class of CA inhibitors.

Identifiants

pubmed: 35188025
doi: 10.1080/14756366.2022.2041630
pmc: PMC8865125
doi:

Substances chimiques

Antigens, Neoplasm 0
Carbonic Anhydrase Inhibitors 0
Isocoumarins 0
CA9 protein, human EC 4.2.1.1
Carbonic Anhydrase IX EC 4.2.1.1
Carbonic Anhydrases EC 4.2.1.1
carbonic anhydrase XII EC 4.2.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

743-748

Références

J Enzyme Inhib Med Chem. 2020 Dec;35(1):1462-1470
pubmed: 32779543
Semin Thromb Hemost. 2019 Jul;45(5):490-501
pubmed: 31216588
J Med Chem. 2012 Jun 14;55(11):5591-600
pubmed: 22621623
Phytochemistry. 2021 Jan;181:112568
pubmed: 33166749
Chem Biol Drug Des. 2011 Jun;77(6):494-9
pubmed: 21332948
Eur J Med Chem. 2021 Dec 15;226:113875
pubmed: 34634741
J Enzyme Inhib Med Chem. 2017 Dec;32(1):1305-1312
pubmed: 29072105
J Enzyme Inhib Med Chem. 2022 Dec;37(1):333-338
pubmed: 34979838
J Med Chem. 2011 Mar 24;54(6):1896-902
pubmed: 21361354
Bioorg Med Chem. 2019 Mar 1;27(5):800-804
pubmed: 30683554
Curr Med Chem. 2010;17(13):1325-38
pubmed: 20166938
Chemistry. 2021 Jun 4;27(32):8232
pubmed: 34028103
J Biomol Screen. 2008 Apr;13(4):265-75
pubmed: 18349420
Bioorg Med Chem. 2019 Apr 15;27(8):1588-1594
pubmed: 30846402
Bioorg Med Chem Lett. 2011 Jul 15;21(14):4259-62
pubmed: 21669522
Molecules. 2018 Jan 27;23(2):
pubmed: 29382051
Radiother Oncol. 2011 Jun;99(3):424-31
pubmed: 21676479
ACS Med Chem Lett. 2017 Nov 21;8(12):1314-1319
pubmed: 29259754
J Nat Prod. 2021 May 28;84(5):1434-1441
pubmed: 33979168
Clin Sci (Lond). 2021 May 28;135(10):1233-1249
pubmed: 34013961
J Enzyme Inhib Med Chem. 2017 Dec;32(1):1174-1182
pubmed: 28891347
Future Med Chem. 2019 May;11(9):1057-1082
pubmed: 31140865
Bioorg Med Chem Lett. 2005 Jun 15;15(12):3102-8
pubmed: 15905091
J Med Chem. 2006 Nov 30;49(24):7024-31
pubmed: 17125255
Front Chem. 2021 Aug 12;9:664489
pubmed: 34458231
Bioorg Med Chem. 2016 Mar 1;24(5):1095-105
pubmed: 26810710
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1193-1198
pubmed: 31237157
Expert Opin Ther Pat. 2018 Mar;28(3):211-226
pubmed: 29324067
Angew Chem Int Ed Engl. 2020 Oct 12;59(42):18709-18716
pubmed: 32567075
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1702-1714
pubmed: 34325588
Expert Opin Investig Drugs. 2021 Dec;30(12):1197-1208
pubmed: 34865569
J Enzyme Inhib Med Chem. 2021 Dec;36(1):561-580
pubmed: 33615947
Bioorg Chem. 2019 Feb;82:117-122
pubmed: 30312866
Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4231-5
pubmed: 24623670
Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jan 5;224:117402
pubmed: 31400747
Chem Commun (Camb). 2014 Jun 7;50(45):5980-3
pubmed: 24763985
J Med Chem. 2004 Apr 22;47(9):2337-47
pubmed: 15084132
J Pharm Sci. 1994 Jun;83(6):768-73
pubmed: 9120804
J Biol Chem. 1971 Apr 25;246(8):2561-73
pubmed: 4994926
J Med Chem. 2010 Jan 14;53(1):335-44
pubmed: 19911821
Bioorg Chem. 2018 Apr;77:245-251
pubmed: 29421699
J Med Chem. 2016 May 26;59(10):5077-88
pubmed: 27144971
Bioorg Med Chem Lett. 2004 Feb 23;14(4):869-73
pubmed: 15012984
Biomolecules. 2020 May 15;10(5):
pubmed: 32429259
J Am Chem Soc. 2009 Mar 4;131(8):3057-62
pubmed: 19206230
Org Biomol Chem. 2015 Jun 21;13(23):6493-9
pubmed: 25967275
Future Med Chem. 2021 Nov;13(22):1935-1937
pubmed: 34498952

Auteurs

Mehmet Onyılmaz (M)

Faculty of Science and Arts, Department of Chemistry, Harran University, Şanlıurfa, Turkey.

Murat Koca (M)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Adıyaman University, Adıyaman, Turkey.

Alessandro Bonardi (A)

Department of Neurofarba, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze, Sesto Fiorentino, Italy.

Mustafa Degirmenci (M)

Faculty of Science and Arts, Department of Chemistry, Harran University, Şanlıurfa, Turkey.

Claudiu T Supuran (CT)

Department of Neurofarba, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze, Sesto Fiorentino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH